Bausch & Lomb Corp BLCO
Bausch & Lomb Corp (BLCO) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $5.1B at a -7.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-04-30 | Evercore ISI Group | In-Line (main) |
| 2026-04-06 | Evercore ISI Group | In-Line (main) |
| 2026-02-23 | HC Wainwright & Co. | Buy (main) |
| 2026-02-19 | Citigroup | Buy (main) |
| 2026-02-19 | Barclays | Equal-Weight (main) |
| 2026-02-19 | Stifel | Hold (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.075 |
| Retained earnings / assets | -0.066 |
| EBIT / assets | 0.008 |
| Equity / liabilities | 0.869 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BLCO | Bausch & Lomb Corp | 3/9 | 1.24 | — | +6.5% |
| COO | COOPER COMPANIES, INC. | 6/9 | 4.99 | 36.9 | +5.1% |
| EYE | National Vision Holdings, Inc. | 7/9 | 0.82 | 51 | +9% |
| WRBY | Warby Parker Inc. | 5/9 | -0.22 | — | +13% |
| STAA | STAAR SURGICAL CO | 1/9 | 4.46 | — | -23.7% |
| RXST | RxSight, Inc. | 2/9 | 5.56 | — | -3.9% |
| LUCY | Innovative Eyewear Inc | 4/9 | — | — | — |
About Bausch & Lomb Corp
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
FAQ
Is BLCO financially healthy?
Bausch & Lomb Corp's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does BLCO pay a dividend?
No, Bausch & Lomb Corp does not currently pay a dividend.
How profitable is BLCO?
In FY2025, Bausch & Lomb Corp had a net margin of -7.1% and a return on equity of -5.5%.
What is the analyst price target for BLCO?
The average Wall-Street price target for Bausch & Lomb Corp is $17.88, about 6.7% above the recent price, from 12 analysts (consensus: buy).
Is BLCO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Bausch & Lomb Corp: a Piotroski F-score of 3/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.